BeiGene (BGNE) Stock Forecast, Price Target & Predictions
BGNE Stock Forecast
BeiGene stock forecast is as follows: an average price target of $255.80 (represents a 23.43% upside from BGNE’s last price of $207.25) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
BGNE Price Target
The average price target for BeiGene (BGNE) is $255.80 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $307.00 to $196.00. This represents a potential 23.43% upside from BGNE's last price of $207.25.
BGNE Analyst Ratings
According to 11 Wall Street analysts, BeiGene's rating consensus is 'Buy'. The analyst rating breakdown for BGNE stock is 0 'Strong Buy' (0.00%), 8 'Buy' (72.73%), 3 'Hold' (27.27%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BeiGene Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 18, 2024 | Reni Benjamin | JMP Securities | $288.00 | $197.51 | 45.82% | 38.96% |
| Aug 23, 2024 | Matthew Harrison | Morgan Stanley | $307.00 | $193.57 | 58.60% | 48.13% |
| May 09, 2024 | Kelly Shi | Jefferies | $283.00 | $164.44 | 72.10% | 36.55% |
| Jun 30, 2023 | Rebecca Liang | Bernstein | $196.00 | $178.46 | 9.83% | -5.43% |
| Oct 13, 2022 | Michael Schmidt | Guggenheim | $205.00 | $151.30 | 35.49% | -1.09% |
The latest BeiGene stock forecast, released on Sep 18, 2024 by Reni Benjamin from JMP Securities, set a price target of $288.00, which represents a 45.82% increase from the stock price at the time of the forecast ($197.51), and a 38.96% increase from BGNE last price ($207.25).
BeiGene Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $297.50 | $292.67 |
| Last Closing Price | $207.25 | $207.25 | $207.25 |
| Upside/Downside | -100.00% | 43.55% | 41.22% |
In the current month, the average price target of BeiGene stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BeiGene's last price of $207.25. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 18, 2024 | Johnson Rice | - | Market Perform | Initialise |
| Sep 18, 2024 | JMP Securities | Market Outperform | Outperform | Initialise |
| Sep 18, 2024 | JMP Securities | - | Market Outperform | Initialise |
| Aug 23, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 08, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 22, 2024 | Jefferies | Buy | Buy | Hold |
| May 09, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 09, 2024 | Jefferies | Buy | Buy | Hold |
| Apr 08, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| Sep 21, 2023 | Citigroup | Buy | Buy | Hold |
BeiGene's last stock rating was published by Johnson Rice on Sep 18, 2024. The company Initialise its BGNE rating from "null" to "Market Perform".
BeiGene Financial Forecast
BeiGene Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $781.31M | $595.26M | $447.80M | $380.10M | $387.63M | $341.57M | $306.63M | $213.98M | $206.44M | $149.99M | $605.87M | $100.10M | $91.08M | $65.64M | $52.06M | $56.89M | $50.14M |
| Avg Forecast | $1.37B | $1.29B | $1.27B | $1.24B | $1.21B | $1.16B | $1.11B | $1.07B | $1.04B | $983.27M | $810.34M | $670.09M | $637.01M | $596.75M | $501.07M | $444.20M | $388.17M | $385.69M | $313.18M | $260.37M | $214.58M | $186.26M | $175.82M | $258.05M | $121.53M | $86.28M | $64.76M | $49.12M | $60.25M | $65.43M |
| High Forecast | $1.37B | $1.29B | $1.27B | $1.24B | $1.21B | $1.16B | $1.11B | $1.07B | $1.04B | $1.02B | $810.34M | $670.09M | $694.19M | $601.85M | $501.07M | $444.20M | $388.17M | $385.69M | $313.18M | $260.37M | $214.58M | $186.26M | $175.82M | $258.05M | $121.53M | $86.28M | $64.76M | $49.12M | $60.25M | $65.43M |
| Low Forecast | $1.37B | $1.29B | $1.27B | $1.24B | $1.21B | $1.16B | $1.11B | $1.07B | $1.04B | $940.02M | $810.34M | $670.09M | $592.44M | $591.65M | $501.07M | $444.20M | $388.17M | $385.69M | $313.18M | $260.37M | $214.58M | $186.26M | $175.82M | $258.05M | $121.53M | $86.28M | $64.76M | $49.12M | $60.25M | $65.43M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.31% | 1.19% | 1.01% | 0.98% | 1.01% | 1.09% | 1.18% | 1.00% | 1.11% | 0.85% | 2.35% | 0.82% | 1.06% | 1.01% | 1.06% | 0.94% | 0.77% |
BeiGene's average Quarter revenue forecast for Dec 23 based on 6 analysts is $637.01M, with a low forecast of $592.44M, and a high forecast of $694.19M. BGNE's average Quarter revenue forecast represents a -18.47% decrease compared to the company's last Quarter revenue of $781.31M (Sep 23).
BeiGene EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-133.97M | $-296.38M | $-371.26M | $-468.43M | $-422.16M | $-439.21M | $-443.10M | $-586.62M | $-420.90M | $-469.04M | $71.50M | $-474.24M | $-425.30M | $-328.81M | $-354.43M | $-373.02M | $-306.55M |
| Avg Forecast | $-1.22B | $-1.15B | $-1.13B | $-1.11B | $-1.08B | $-1.03B | $-986.02M | $-950.81M | $-927.30M | $-876.20M | $-722.10M | $-545.09M | $-567.65M | $-531.77M | $-446.50M | $-495.54M | $-391.61M | $-343.69M | $-279.07M | $-450.49M | $-191.22M | $-165.98M | $-156.67M | $144.78M | $-108.30M | $-76.88M | $-57.71M | $-365.39M | $-53.69M | $-58.31M |
| High Forecast | $-1.22B | $-1.15B | $-1.13B | $-1.11B | $-1.08B | $-1.03B | $-986.02M | $-950.81M | $-927.30M | $-837.66M | $-722.10M | $-436.07M | $-527.92M | $-527.22M | $-446.50M | $-396.43M | $-313.29M | $-343.69M | $-279.07M | $-360.39M | $-191.22M | $-165.98M | $-156.67M | $173.74M | $-108.30M | $-76.88M | $-57.71M | $-292.31M | $-53.69M | $-58.31M |
| Low Forecast | $-1.22B | $-1.15B | $-1.13B | $-1.11B | $-1.08B | $-1.03B | $-986.02M | $-950.81M | $-927.30M | $-905.98M | $-722.10M | $-654.11M | $-618.60M | $-536.31M | $-446.50M | $-594.65M | $-469.94M | $-343.69M | $-279.07M | $-540.59M | $-191.22M | $-165.98M | $-156.67M | $115.83M | $-108.30M | $-76.88M | $-57.71M | $-438.47M | $-53.69M | $-58.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.25% | 0.66% | 0.75% | 1.20% | 1.23% | 1.57% | 0.98% | 3.07% | 2.54% | 2.99% | 0.49% | 4.38% | 5.53% | 5.70% | 0.97% | 6.95% | 5.26% |
3 analysts predict BGNE's average Quarter EBITDA for Jun 21 to be $-156.67M, with a high of $-156.67M and a low of $-156.67M. This is -319.13% lower than BeiGene's previous annual EBITDA (Mar 21) of $71.50M.
BeiGene Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $215.41M | $-381.14M | $-348.43M | $-445.33M | $-557.56M | $-571.45M | $-434.27M | $-585.65M | $-413.86M | $-480.34M | $66.50M | $-472.75M | $-425.22M | $-335.20M | $-363.74M | $-388.06M | $-307.36M |
| Avg Forecast | $109.52M | $54.40M | $40.34M | $14.37M | $-9.85M | $-31.26M | $-47.32M | $-91.95M | $-112.82M | $-108.86M | $-229.22M | $-599.93M | $-365.26M | $-354.39M | $-351.93M | $-545.39M | $-390.97M | $-409.29M | $-419.65M | $-495.81M | $-520.67M | $-492.12M | $-391.46M | $134.65M | $-442.85M | $-431.36M | $-500.01M | $-374.98M | $-502.59M | $-404.29M |
| High Forecast | $109.52M | $54.40M | $40.34M | $14.37M | $-9.85M | $-31.26M | $-47.32M | $-91.95M | $-112.82M | $-22.27M | $-229.22M | $-479.94M | $-114.53M | $-354.39M | $-351.93M | $-436.31M | $-312.78M | $-409.29M | $-419.65M | $-396.65M | $-520.67M | $-492.12M | $-391.46M | $161.58M | $-442.85M | $-431.36M | $-500.01M | $-299.99M | $-502.59M | $-404.29M |
| Low Forecast | $109.52M | $54.40M | $40.34M | $14.37M | $-9.85M | $-31.26M | $-47.32M | $-91.95M | $-112.82M | $-200.39M | $-229.22M | $-719.92M | $-503.01M | $-354.39M | $-351.93M | $-654.47M | $-469.16M | $-409.29M | $-419.65M | $-594.97M | $-520.67M | $-492.12M | $-391.46M | $107.72M | $-442.85M | $-431.36M | $-500.01M | $-449.98M | $-502.59M | $-404.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.61% | 1.08% | 0.64% | 1.14% | 1.36% | 1.36% | 0.88% | 1.12% | 0.84% | 1.23% | 0.49% | 1.07% | 0.99% | 0.67% | 0.97% | 0.77% | 0.76% |
BeiGene's average Quarter net income forecast for Dec 23 is $-365.26M, with a range of $-503.01M to $-114.53M. BGNE's average Quarter net income forecast represents a -269.56% decrease compared to the company's last Quarter net income of $215.41M (Sep 23).
BeiGene SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $364.42M | $395.03M | $328.50M | $328.98M | $322.89M | $331.40M | $294.57M | $306.50M | $269.23M | $232.29M | $182.11M | $208.21M | $160.84M | $124.05M | $107.08M | $143.35M | $105.00M |
| Avg Forecast | $1.43B | $1.35B | $1.32B | $1.29B | $1.26B | $1.21B | $1.15B | $1.11B | $1.08B | $1.02B | $843.71M | $406.94M | $663.25M | $621.33M | $521.70M | $369.95M | $204.61M | $401.57M | $326.07M | $271.10M | $223.42M | $193.93M | $183.06M | $268.68M | $126.53M | $89.83M | $67.43M | $51.14M | $62.73M | $68.13M |
| High Forecast | $1.43B | $1.35B | $1.32B | $1.29B | $1.26B | $1.21B | $1.15B | $1.11B | $1.08B | $1.06B | $843.71M | $488.33M | $722.78M | $626.63M | $521.70M | $443.93M | $245.54M | $401.57M | $326.07M | $271.10M | $223.42M | $193.93M | $183.06M | $268.68M | $126.53M | $89.83M | $67.43M | $51.14M | $62.73M | $68.13M |
| Low Forecast | $1.43B | $1.35B | $1.32B | $1.29B | $1.26B | $1.21B | $1.15B | $1.11B | $1.08B | $978.73M | $843.71M | $325.55M | $616.83M | $616.02M | $521.70M | $295.96M | $163.69M | $401.57M | $326.07M | $271.10M | $223.42M | $193.93M | $183.06M | $268.68M | $126.53M | $89.83M | $67.43M | $51.14M | $62.73M | $68.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.59% | 0.76% | 0.89% | 1.61% | 0.80% | 1.02% | 1.09% | 1.37% | 1.39% | 1.27% | 0.68% | 1.65% | 1.79% | 1.84% | 2.09% | 2.29% | 1.54% |
BeiGene's average Quarter SG&A projection for Dec 23 is $663.25M, based on 6 Wall Street analysts, with a range of $616.83M to $722.78M. The forecast indicates a 82.00% rise compared to BGNE last annual SG&A of $364.42M (Sep 23).
BeiGene EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.58 | $-3.64 | $-3.34 | $-4.29 | $-5.39 | $-5.56 | $-4.24 | $-6.16 | $-4.68 | $-5.20 | $0.78 | $-5.20 | $-4.81 | $-4.29 | $-4.70 | $-6.37 | $-5.07 |
| Avg Forecast | $1.05 | $0.52 | $0.39 | $0.14 | $-0.09 | $-0.30 | $-0.45 | $-0.88 | $-1.08 | $-1.04 | $-2.19 | $-3.09 | $-3.49 | $-3.38 | $-3.36 | $-3.66 | $-4.64 | $-3.91 | $-4.01 | $-4.12 | $-4.97 | $-4.70 | $-3.74 | $-1.90 | $-4.23 | $-4.12 | $-4.78 | $-4.85 | $-4.80 | $-3.86 |
| High Forecast | $1.05 | $0.52 | $0.39 | $0.14 | $-0.09 | $-0.30 | $-0.45 | $-0.88 | $-1.08 | $-0.21 | $-2.19 | $-3.09 | $-1.09 | $-3.38 | $-3.36 | $-3.66 | $-4.64 | $-3.91 | $-4.01 | $-4.12 | $-4.97 | $-4.70 | $-3.74 | $-1.90 | $-4.23 | $-4.12 | $-4.78 | $-4.85 | $-4.80 | $-3.86 |
| Low Forecast | $1.05 | $0.52 | $0.39 | $0.14 | $-0.09 | $-0.30 | $-0.45 | $-0.88 | $-1.08 | $-1.91 | $-2.19 | $-3.09 | $-4.80 | $-3.38 | $-3.36 | $-3.66 | $-4.64 | $-3.91 | $-4.01 | $-4.12 | $-4.97 | $-4.70 | $-3.74 | $-1.90 | $-4.23 | $-4.12 | $-4.78 | $-4.85 | $-4.80 | $-3.86 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.47% | 1.08% | 0.91% | 0.93% | 1.38% | 1.39% | 1.03% | 1.24% | 1.00% | 1.39% | -0.41% | 1.23% | 1.17% | 0.90% | 0.97% | 1.33% | 1.31% |
According to 6 Wall Street analysts, BeiGene's projected average Quarter EPS for Dec 23 is $-3.49, with a low estimate of $-4.80 and a high estimate of $-1.09. This represents a -320.81% decrease compared to BGNE previous annual EPS of $1.58 (Sep 23).
BeiGene Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IMAB | I-Mab | $1.09 | $35.00 | 3111.01% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $20.06 | $45.38 | 126.22% | Buy |
| LEGN | Legend Biotech | $43.61 | $82.62 | 89.45% | Buy |
| BMRN | BioMarin Pharmaceutical | $66.01 | $101.70 | 54.07% | Buy |
| ASND | Ascendis Pharma | $125.77 | $190.21 | 51.24% | Buy |
| IMVT | Immunovant | $29.42 | $42.83 | 45.58% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| IONS | Ionis Pharmaceuticals | $38.44 | $51.68 | 34.44% | Buy |
| BGNE | BeiGene | $207.25 | $255.80 | 23.43% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| TVTX | Travere Therapeutics | $18.10 | $21.38 | 18.12% | Buy |
| PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| INCY | Incyte | $75.75 | $84.56 | 11.63% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |
BGNE Forecast FAQ
Is BeiGene a good buy?
Yes, according to 11 Wall Street analysts, BeiGene (BGNE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 72.73% of BGNE's total ratings.
What is BGNE's price target?
BeiGene (BGNE) average price target is $255.8 with a range of $196 to $307, implying a 23.43% from its last price of $207.25. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will BeiGene stock go up soon?
According to Wall Street analysts' prediction for BGNE stock, the company can go up by 23.43% (from the last price of $207.25 to the average price target of $255.8), up by 48.13% based on the highest stock price target, and down by -5.43% based on the lowest stock price target.
Can BeiGene stock reach $300?
BGNE's highest twelve months analyst stock price target of $307 supports the claim that BeiGene can reach $300 in the near future.
What are BeiGene's analysts' financial forecasts?
BeiGene's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.54B (high $4.54B, low $4.54B), average EBITDA is $-4.049B (high $-4.049B, low $-4.049B), average net income is $-180M (high $-180M, low $-180M), average SG&A $4.73B (high $4.73B, low $4.73B), and average EPS is $-1.723 (high $-1.723, low $-1.723). BGNE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.17B (high $5.17B, low $5.17B), average EBITDA is $-4.608B (high $-4.608B, low $-4.608B), average net income is $218.63M (high $218.63M, low $218.63M), average SG&A $5.38B (high $5.38B, low $5.38B), and average EPS is $2.09 (high $2.09, low $2.09).
Did the BGNE's actual financial results beat the analysts' financial forecasts?
Based on BeiGene's last annual report (Dec 2023), the company's revenue was $2.46B, beating the average analysts forecast of $2.18B by 12.84%. Apple's EBITDA was $-1.208B, missing the average prediction of $-2.041B by -40.84%. The company's net income was $-882M, missing the average estimation of $-1.617B by -45.47%. Apple's SG&A was $1.5B, missing the average forecast of $2.18B by -30.87%. Lastly, the company's EPS was $-0.0006, missing the average prediction of $-13.898 by -100.00%. In terms of the last quarterly report (Sep 2023), BeiGene's revenue was $781.31M, beating the average analysts' forecast of $596.75M by 30.93%. The company's EBITDA was $-134M, missing the average prediction of $-532M by -74.81%. BeiGene's net income was $215.41M, missing the average estimation of $-354M by -160.79%. The company's SG&A was $364.42M, missing the average forecast of $621.33M by -41.35%. Lastly, the company's EPS was $1.58, missing the average prediction of $-3.385 by -146.68%